Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKodiak Sciences Inc

Kodiak Sciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
106.26 USD 6.96 ( 7.01%)
Last update at 2026-11-09T15:40:00Z
VOLUME
399698
Market Cap
2073.40M

Momentum Score

…

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
99.56
Low
107.42
High
52 Week Price Range
9.22
Low
47.84
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kodiak Sciences is a clinical-stage biopharmaceutical company developing intravitreal therapies for retinal vascular diseases, with lead candidate KSI-301 an investigational anti-VEGF antibody-biopolymer conjugate designed to extend dosing durability across DME, neovascular AMD and RVO. Long-term growth may come from successful trials, regulatory approvals and partnerships, which may attract investors as a durable therapy could lower treatment frequency and reduce patient burden.

Material risks include clinical and regulatory failure for the lead program, intense competition from established and emerging anti-VEGF therapies, reliance on a single asset, and potential need for financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
99.30
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
1.01
ROE
-368.37%
Net Debt
-50.68M
ROCE
-75.15%
Diluted EPS TTM
-4.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -229.97M -176.21M -260.49M -333.82M -266.99M
Net income -229.97M -176.21M -260.49M 339738.18M -258.09M
Selling general administrative 52.02M 60.75M 71.02M 73.79M 49.71M
Selling and marketing expenses - - 45.00M - -
Gross profit - -26.71M -25.95M - -
Reconciled depreciation 26.32M 26.71M 25.95M 11.00M 8.71M
Ebit -229.97M -176.21M -260.48M -341.38M -267.05M
Ebitda -203.65M -149.50M -234.53M -333.81M -266.97M
Depreciation and amortization 26.32M 26.71M 25.95M 7.57M 0.08M
Non operating income net other - - - 7.57M 0.08M
Operating income -234.39M -186.85M -277.32M -341.38M -267.05M
Other operating expenses 234.39M 186.85M 277.32M 341.38M 267.05M
Interest expense 0.00M 0.00M 0.01M 0.02M 0.02M
Interest income 4.52M 11.15M 16.73M 7.07M 0.30M
Net interest income 4.52M 11.15M 16.72M 7.05M 0.28M
Income tax expense - - - -340072.00M -8.90M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 234.39M 160.14M 251.37M 341.38M 267.05M
Cost of revenue - 26.71M 25.95M - -
Total other income expense net 4.42M 10.64M 16.83M 7.56M 0.06M
Net income from continuing ops -229.97M -176.21M -260.49M -333.82M -266.99M
Net income applicable to common shares - - - -333.82M -266.99M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 351.53M 335.58M 479.37M 666.63M 904.22M
Other current assets 4.95M 3.86M 3.80M 7.07M 3.30M
Total liab 194.15M 185.29M 213.59M 230.46M 240.90M
Total stockholder equity 157.38M 150.29M 265.78M 436.17M -558.22M
Other current liab 20.61M 11.03M 18.35M 33.44M 48.32M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1558.70M -1328.74M -1152.53M -892.04M -558.22M
Other liab - - - - 100.15M
Other assets - - - 64.87M 61.34M
Cash 209.86M 168.07M 285.51M 190.43M 731.51M
Total current liabilities 45.53M 25.57M 41.73M 52.50M 64.68M
Net debt -50.68M -97.73M -103.88M -102.70M -651.51M
Short term debt 12.06M 10.63M 9.77M 9.93M 3.93M
Short long term debt total 159.18M 70.34M 181.63M 87.73M 80.00M
Other stockholder equity 1716.08M 1479.02M 1418.31M 1329.51M -0.01M
Property plant equipment - - - 56.38M 108.07M
Total current assets 214.82M 171.94M 289.31M 486.00M 734.81M
Net tangible assets - - - 436.17M 663.32M
Short term investments - - 0.00M 288.50M -
Accounts payable 12.86M 3.92M 13.61M 9.13M 12.43M
Accumulated other comprehensive income - - - -1.31M -
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -892.04M -558.22M
Non currrent assets other 8.67M 8.73M 8.72M 64.87M 61.34M
Non current assets total 136.72M 163.64M 190.06M 180.62M 169.41M
Capital lease obligations 59.18M 70.34M 81.63M 87.73M 80.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -0.76M 249.23M -289.15M 24.50M
Change to liabilities - - - -0.59M -2.09M
Total cashflows from investing activities -0.51M -0.76M 249.23M -336.51M -38.80M
Total cash from financing activities 178.30M 0.50M 0.03M 1.90M 8.18M
Change to operating activities - - - 10.30M 16.52M
Net income -229.97M -176.21M -260.49M -333.82M -266.99M
Change in cash 41.79M -117.57M 95.07M -541.08M -212.89M
Begin period cash flow 174.26M 291.83M 190.43M 737.83M 950.72M
End period cash flow 216.05M 174.26M 285.51M 196.76M 737.83M
Total cash from operating activities -136.01M -117.32M -154.18M -206.46M -182.27M
Issuance of capital stock 172.96M 0.00M 0.00M 0.00M 0.00M
Depreciation 18.33M 26.71M 25.95M 11.00M 8.71M
Other cashflows from investing activities - -0.76M 0.29M -10.34M -46.27M
Sale purchase of stock - - - 0.17M 0.48M
Other cashflows from financing activities - 0.50M -0.21M -0.05M 7.70M
Change to netincome - - - 105.42M 61.53M
Capital expenditures 0.51M 0.40M 41.43M 47.36M 63.30M
Cash flows other operating - - - 19.80M 10.89M
Cash and cash equivalents changes - - - -541.08M -212.89M
Change in working capital 6.85M -28.39M -7.36M 11.96M 14.43M
Stock based compensation 58.86M 60.21M 88.56M 106.03M 61.38M
Other non cash items 9.92M 0.35M -0.84M -1.63M 0.05M
Free cash flow -136.51M -117.72M -195.61M -253.82M -245.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
KOD
Kodiak Sciences Inc		 6.96
7.01%		 106.26 - - - 34.10 -0.12
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

1250 Page Mill Road, Palo Alto, CA, United States, 94304

650 281 0850

https://kodiak.com

141

Name Title Year Born
Dr. Victor Perlroth M.D. Co-Founder, Chairman, CEO & Pres 1973
Mr. John A. Borgeson CPA, M.B.A., MBA, CPA Sr. VP, CFO & Sec. 1962
Dr. Jason S. Ehrlich M.D., Ph.D. Chief Medical Officer & Chief Devel. Officer 1976
Dr. Michael S. Louie Ph.D. Sr. VP of Digital Transformation & Chief Information Officer NA
Dr. Hong Liang Sr. VP of Discovery Medicine 1972
Ms. Almas Qudrat M.Sc. Sr. VP of Quality Operations NA
Dr. Victor Perlroth M.D. Co-Founder, Chairman, CEO & President 1973
Mr. John A. Borgeson CPA, M.B.A. Senior VP, CFO & Secretary 1962
Dr. Michael S. Louie Ph.D. Senior VP of Digital Transformation & Chief Information Officer NA
Dr. Hong Liang Senior Vice President of Discovery Medicine 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…